Top PDF The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
... that the improved response and survival for patients whose tumors express NY-ESO-1 were not the result of increased cytotoxicity, but rather were mediated through immunological ...stimulator ...
8
The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer: a systematic review and meta-analysis.
... because of insuffi- cient information. Titles and abstracts were examined at first to eliminate not applicable stud- ies, such as studies on animals or cell lines, reviews and studies about ...
13
The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis.
... Lung cancer is one of the most common human cancers and the leading cause of cancer-related deaths with non-small cell lung ...
6
Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis.
... However, in most of the studies, arterial and venous invasion has not been separately studied pathologically due to the inability in some cases to discriminate between arterial ...
8
Proportional weight loss in six months as a risk factor for mortality in stage IV non- small cell lung cancer
... as prognostic markers of 3-month survival after diagnosis of stage IV non-small cell lung cancer ...a cancer treatment center in southern ...
5
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice
... [3] in a study to understand the biologic process underlying the differentiation of reticulocytes to mature ...erythrocytes. The authors observed that maturing reticulocytes contained ...
13
Potential role of immunotherapy in advanced non-small-cell lung cancer
... redirect and reprogram patient T-cells have shown promising results in the treatment of acute lympho- blastic leukemia and non-Hodgkin’s ...with the ability to target ...
10
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
... early-stage non-small-cell lung cancer (NSCLC) is considered a potentially curable disease following complete resection, patients have a wide spectrum of survival according to ...
7
Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
... Potential of POTEE as a Serologic Tumor Biomarker in NSCLC A ROC curve analysis was carried out to assess the value of POTEE in NSCLC ...reflect the sensitivity and ...
10
Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
... combination of LMR and MBR could predict prognosis in EGFR -mutant NSCLC patients receiving first-line ...PS, and a lower incidence of brain and distant ...tant role ...
13
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.
... considered the key molecule because it is the only member of the PA family shown to accelerate cell migration in ...vitro. In comparison, our IHC data demonstrated no ...
15
THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.
... Firstly the increase in platelet count may promote tumor cells growth and ...(VEGF) and platelet- derived growth factor (PDGF), during blood clotting. The VEGF and PDGF fam- ily ...
5
Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients.
... level and treatment response ...patients and found to be only useful in patients with an increased pre-treatment level ...[29]. The levels of lactate dehydrogenase and ...
10
Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer.
... showed the strongest correlation with the positive DTC ...among the bone marrow- positive NSCLC patients, indicating a likely presence of tumor suppressor genes within this region ...[14]. ...
17
Nuclear survivin and its relationship to DNA damage repair genes in non-small cell lung cancer investigated using tissue array.
... The prognostic predictive value of survivin expression and that of nuclear staining versus cytoplasmic staining in several malig- nancies, including NSCLC, have been ...
10
Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort.
... inflammation, cancer can induce local or systemic inflammation, which is mediated by activation of transcription factors and production of major inflammatory cyto- kines ...On the other ...
14
An Overview: Treatment of Lung Cancer on Researcher Point of View
... Correlate the inhibitor of gefitinib this inhibitor for signaling to increase ...grows. The patients who are affected by gefitinib are exposed to screening for identification of lung ...
7
Analysis of Prognostic Factors in 541 Female Patients with Advanced Non-small Cell Lung Cancer
... predictors of outcome with geitinib in a phase III placebocontrolled study in advanced non-small-cell lung ...impact of induction chemotherapy ...
6
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
... Akt and phospho-Akt (S473), clone D9E were from Cell Signaling Technology (CST); AXL (#AF154) and phospho-AXL (Y779) (#AF228) were from R&D Systems; GAPDH, clone 1D4 or #5174 was respectively ...
22
Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: a systematic review and meta-analysis.
... regarding the effects of PCI on toxicity and QOL in patients with ...because the related symptoms can be caused by many different ...dose and fractionation scheme (fraction size ...
12
